Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy
RNA-based therapy is a promising and innovative strategy for cancer treatment. However, poor stability, immunogenicity, low cellular uptake rate, and difficulty in endosomal escape are considered the major obstacles in the cancer therapy process, severely limiting the development of clinical transla...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Bioengineering |
Subjects: | |
Online Access: | https://www.mdpi.com/2306-5354/9/10/576 |
_version_ | 1797475229973348352 |
---|---|
author | Shuaiying Wu Chao Liu Shuang Bai Zhixiang Lu Gang Liu |
author_facet | Shuaiying Wu Chao Liu Shuang Bai Zhixiang Lu Gang Liu |
author_sort | Shuaiying Wu |
collection | DOAJ |
description | RNA-based therapy is a promising and innovative strategy for cancer treatment. However, poor stability, immunogenicity, low cellular uptake rate, and difficulty in endosomal escape are considered the major obstacles in the cancer therapy process, severely limiting the development of clinical translation and application. For efficient and safe transport of RNA into cancer cells, it usually needs to be packaged in appropriate carriers so that it can be taken up by the target cells and then be released to the specific location to perform its function. In this review, we will focus on up-to-date insights of the RNA-based delivery carrier and comprehensively describe its application in cancer therapy. We briefly discuss delivery obstacles in RNA-mediated cancer therapy and summarize the advantages and disadvantages of different carriers (cationic polymers, inorganic nanoparticles, lipids, etc.). In addition, we further summarize and discuss the current RNA therapeutic strategies approved for clinical use. A comprehensive overview of various carriers and emerging delivery strategies for RNA delivery, as well as the current status of clinical applications and practice of RNA medicines are classified and integrated to inspire fresh ideas and breakthroughs. |
first_indexed | 2024-03-09T20:41:12Z |
format | Article |
id | doaj.art-d1b1a92c6d074694998637026b100a83 |
institution | Directory Open Access Journal |
issn | 2306-5354 |
language | English |
last_indexed | 2024-03-09T20:41:12Z |
publishDate | 2022-10-01 |
publisher | MDPI AG |
record_format | Article |
series | Bioengineering |
spelling | doaj.art-d1b1a92c6d074694998637026b100a832023-11-23T22:58:07ZengMDPI AGBioengineering2306-53542022-10-0191057610.3390/bioengineering9100576Broadening the Horizons of RNA Delivery Strategies in Cancer TherapyShuaiying Wu0Chao Liu1Shuang Bai2Zhixiang Lu3Gang Liu4State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, ChinaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & Center for Molecular Imaging and Translational Medicine, School of Public Health, Xiamen University, Xiamen 361102, ChinaRNA-based therapy is a promising and innovative strategy for cancer treatment. However, poor stability, immunogenicity, low cellular uptake rate, and difficulty in endosomal escape are considered the major obstacles in the cancer therapy process, severely limiting the development of clinical translation and application. For efficient and safe transport of RNA into cancer cells, it usually needs to be packaged in appropriate carriers so that it can be taken up by the target cells and then be released to the specific location to perform its function. In this review, we will focus on up-to-date insights of the RNA-based delivery carrier and comprehensively describe its application in cancer therapy. We briefly discuss delivery obstacles in RNA-mediated cancer therapy and summarize the advantages and disadvantages of different carriers (cationic polymers, inorganic nanoparticles, lipids, etc.). In addition, we further summarize and discuss the current RNA therapeutic strategies approved for clinical use. A comprehensive overview of various carriers and emerging delivery strategies for RNA delivery, as well as the current status of clinical applications and practice of RNA medicines are classified and integrated to inspire fresh ideas and breakthroughs.https://www.mdpi.com/2306-5354/9/10/576RNA deliverydelivery carriercancer therapyclinical practice |
spellingShingle | Shuaiying Wu Chao Liu Shuang Bai Zhixiang Lu Gang Liu Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy Bioengineering RNA delivery delivery carrier cancer therapy clinical practice |
title | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_full | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_fullStr | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_full_unstemmed | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_short | Broadening the Horizons of RNA Delivery Strategies in Cancer Therapy |
title_sort | broadening the horizons of rna delivery strategies in cancer therapy |
topic | RNA delivery delivery carrier cancer therapy clinical practice |
url | https://www.mdpi.com/2306-5354/9/10/576 |
work_keys_str_mv | AT shuaiyingwu broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT chaoliu broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT shuangbai broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT zhixianglu broadeningthehorizonsofrnadeliverystrategiesincancertherapy AT gangliu broadeningthehorizonsofrnadeliverystrategiesincancertherapy |